Wanbangde Pharmaceutical Holding Group (002082) Fundamentals 2026 — Revenue Analysis | SniperIQ
Wanbangde Pharmaceutical Holding Group (002082) is a CN-listed Healthcare company in Aluminum with a market capitalization of ¥5.8B, trading at ¥9.55 on the SHZ. This SniperIQ fundamentals page covers Wanbangde Pharmaceutical Holding Group's valuation, profitability (net margin -9.2%), revenue (¥1.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Wanbangde Pharmaceutical Holding Group's market cap?
Wanbangde Pharmaceutical Holding Group (002082) has a market capitalization of approximately ¥5.8B, trading at ¥9.55 on the SHZ. Market cap moves with the live share price.
What is Wanbangde Pharmaceutical Holding Group's P/E ratio?
Wanbangde Pharmaceutical Holding Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Wanbangde Pharmaceutical Holding Group?
Wanbangde Pharmaceutical Holding Group runs a net profit margin of -9.2%, a gross margin of 103.9%, and an operating margin of -5.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Wanbangde Pharmaceutical Holding Group generate?
Wanbangde Pharmaceutical Holding Group reported revenue of ¥1.1B for fiscal year 2025, with net income of -¥167M and earnings per share (EPS) of -0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Wanbangde Pharmaceutical Holding Group pay a dividend?
Wanbangde Pharmaceutical Holding Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Wanbangde Pharmaceutical Holding Group financially healthy?
Wanbangde Pharmaceutical Holding Group carries a debt-to-equity ratio of 0.31x and a current ratio of 1.23x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Wanbangde Pharmaceutical Holding Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wanbangde Pharmaceutical Holding Group (002082) the key facts are: market cap ¥5.8B, revenue ¥1.1B, 52-week range 7.15-36.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Wanbangde Pharmaceutical Holding Group's full fundamentals live
Get Wanbangde Pharmaceutical Holding Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.